NCT03587662View on ClinicalTrials.gov

Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 17, 2018

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions
Metastatic Kidney Medullary CarcinomaMetastatic Renal Cell CarcinomaSMARCB1 NegativeStage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8
Interventions
DRUG

Doxorubicin

Given IV

DRUG

Doxorubicin Hydrochloride

Given IV

DRUG

Gemcitabine

Given IV

DRUG

Gemcitabine Hydrochloride

Given IV

DRUG

Ixazomib

Given PO

DRUG

Ixazomib Citrate

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT03587662 - Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer | Biotech Hunter | Biotech Hunter